Fulgent Genetics Valuation
| FLGT Stock | USD 16.57 0.27 1.60% |
At this time, the firm appears to be undervalued. Fulgent Genetics shows a prevailing Real Value of $17.87 per share. The current price of the firm is $16.57. Our model computes the value of Fulgent Genetics from reviewing the firm fundamentals such as Profit Margin of (0.59) %, shares outstanding of 30.59 M, and Current Valuation of 311.06 M as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Fulgent Genetics' price fluctuation is not too volatile at this time. Calculation of the real value of Fulgent Genetics is based on 3 months time horizon. Increasing Fulgent Genetics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Fulgent Genetics' intrinsic value may or may not be the same as its current market price of 16.57, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.57 | Real 17.87 | Hype 16.57 | Naive 15.47 |
The intrinsic value of Fulgent Genetics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Fulgent Genetics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Fulgent Genetics helps investors to forecast how Fulgent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fulgent Genetics more accurately as focusing exclusively on Fulgent Genetics' fundamentals will not take into account other important factors: Fulgent Genetics Total Value Analysis
Fulgent Genetics is currently forecasted to have valuation of 311.06 M with market capitalization of 515.08 M, debt of 15.25 M, and cash on hands of 515.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fulgent Genetics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
311.06 M | 515.08 M | 15.25 M | 515.4 M |
Fulgent Genetics Investor Information
About 32.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulgent Genetics has Price/Earnings To Growth (PEG) ratio of 1.32. The entity recorded a loss per share of 5.52. The firm had not issued any dividends in recent years. Based on the key indicators related to Fulgent Genetics' liquidity, profitability, solvency, and operating efficiency, Fulgent Genetics is not in a good financial situation at the present time. It has a very high chance of going through financial crunch in March.Fulgent Genetics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fulgent Genetics has an asset utilization ratio of 23.41 percent. This implies that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Fulgent Genetics is more efficient with each dollar of assets it utilizes for everyday operations.Fulgent Genetics Ownership Allocation
Fulgent Genetics holds a total of 30.59 Million outstanding shares. Over half of Fulgent Genetics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fulgent Genetics Profitability Analysis
The company reported the previous year's revenue of 289.21 M. Net Loss for the year was (167.82 M) with profit before overhead, payroll, taxes, and interest of 100.59 M.About Fulgent Genetics Valuation
The stock valuation mechanism determines Fulgent Genetics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Fulgent Genetics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fulgent Genetics. We calculate exposure to Fulgent Genetics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fulgent Genetics's related companies.Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 645 people.
Fulgent Genetics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Fulgent Genetics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.8 M | |
| Quarterly Earnings Growth Y O Y | -0.986 | |
| Forward Price Earnings | 7.9365 |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.